Showing 141 - 160 results of 795 for search 'declaration controller', query time: 0.11s Refine Results
  1. 141
  2. 142
  3. 143

    Effect of music listening on delirium after hip fracture operations (MLDHFO) in a regional hospital in Taiwan: a randomised controlled trial protocol by Ling Wang, Lin-Yu Chao, Chun-Chih Lin, Hsing-Ju Lu, Jiun-Liang Chen, Han-Chang Ku

    Published 2025-08-01
    “…The trial will be carried out following the Declaration of Helsinki principles and Good Clinical Practice guidelines. …”
    Get full text
    Article
  4. 144

    Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF) by Toby M Maher, Michael Kreuter, Vincent Cottin, Susanne Stowasser, Marlies S Wijsenbeek, Yi Liu, Fernando J Martinez, Luca Richeldi, Arata Azuma, Justin M Oldham, Claudia Valenzuela, Maud Gordat, Donald F Zoz

    Published 2023-07-01
    “…Methods and analysis In this placebo-controlled, double-blind, phase III trial, patients are being randomised in a 1:1:1 ratio to receive 9 mg or 18 mg of BI 1015550 or placebo two times per day over at least 52 weeks, stratified by use of background antifibrotics (nintedanib/pirfenidone vs neither). …”
    Get full text
    Article
  5. 145
  6. 146
  7. 147
  8. 148

    Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD) by Toby M Maher, Michael Kreuter, Vincent Cottin, Daniel Wachtlin, Anna-Maria Hoffmann-Vold, Marlies S Wijsenbeek, Fernando J Martinez, Shervin Assassi, Luca Richeldi, Arata Azuma, Justin M Oldham, Claudia Valenzuela, Carl Coeck, Christina Schlecker, Florian Voss

    Published 2023-07-01
    “…Following positive results in a phase II study in IPF, this phase III study will investigate the efficacy and safety of BI 1015550 in patients with PPF (FIBRONEER-ILD).Methods and analysis In this phase III, double-blind, placebo-controlled trial, patients are being randomised 1:1:1 to receive BI 1015550 (9 mg or 18 mg) or placebo twice daily over at least 52 weeks, stratified by background nintedanib use. …”
    Get full text
    Article
  9. 149

    Determinants of Acute Malnutrition among Under-Five Children in Governmental Health Facilities in Sodo Town, Southern Ethiopia: Unmatched Case-Control Study by Zenebe Jebero, Fikre Moga, Bereket Gebremichael, Tewodros Tesfaye

    Published 2023-01-01
    “…A logistic regression model was used to identify the determinants of acute malnutrition, and statistical significance was declared at P<0.05. Result. A total of 133 cases and 266 controls were included in the study making a response rate of 97.8%. …”
    Get full text
    Article
  10. 150

    Sepsis Risk Factors in Neonatal Intensive Care Units of Public Hospitals in Southeast Ethiopia, 2020: A Retrospective Unmatched Case-Control Study by Gemechu Ganfure, Bikila Lencha

    Published 2023-01-01
    “…An adjusted odds ratio with a 95% confidence interval was used to determine the degree of association, and statistical significance was declared at a p value of < 0.05. Results. In this study, 97 cases and 194 controls were included. …”
    Get full text
    Article
  11. 151

    Determinants of compliance with iron-folic acid supplementation among pregnant mothers in Bule Hora district, Southern Ethiopia: unmatched case-control study by Reta Tesfa Merga, Mahlet Birhane, Midhagsaa Dhinsa, Biranu Muleta, Jibril Jemal, Moges Mareg Belay

    Published 2025-03-01
    “…Methods A health facility -based, unmatched case-control study was conducted in Bule Hora district from April 2024 to June 2024, via a pretested interviewer-administered questionnaire. …”
    Get full text
    Article
  12. 152

    Effectiveness of shared decision-making for glycaemic control among type 2 diabetes mellitus adult patients: A systematic review and meta-analysis. by Edosa Tesfaye Geta, Dufera Rikitu Terefa, Wase Benti Hailu, Wolkite Olani, Emiru Merdassa, Markos Dessalegn, Miesa Gelchu, Dereje Chala Diriba

    Published 2024-01-01
    “…Finally, the statistically significant MD of HbA1c% between the intervention groups engaged in SDM and control groups received usual care was declared at P ˂0.05, using a 95% confidence interval (CI).…”
    Get full text
    Article
  13. 153

    The effectiveness of the educational package of happiness skills based on Islamic approach and comparison with Fordyce's happiness package on happiness, life satisfaction and anger... by Tayebe Vahdani Khorram, Fatemeh Fayyaz, j avad Eynypour

    Published 2024-08-01
    “…The purpose of the present study was to evaluate of the effectiveness of the educational package of happiness skills based on the Islamic approach for happiness, life satisfaction and anger control in mothers and compared the results with Fordyce package. …”
    Get full text
    Article
  14. 154

    Intensive and standard group-based treatment for persons with social communication difficulties after an acquired brain injury: study protocol for a randomised controlled trial by Jan Stubberud, Silje Merethe Hansen, Marianne Hjertstedt, Melanie Kirmess

    Published 2019-09-01
    “…The trial will be conducted in accordance with the Declaration of Helsinki and reported in accordance with the Consolidated Standards of Reporting Trials 2010 statement and Standard Protocol Items: Recommendations for Interventional Trials recommendations.Trial registration number NCT03636399.…”
    Get full text
    Article
  15. 155
  16. 156

    Effects of intravenous propofol combined with opioids on euphoria in patients undergoing painless gastrointestinal endoscopy: protocol for a randomized double-blind placebo-control... by Youjia Yu, Qingfang Ma, Fengxia Du, Xiang Zhang, Chunyan Shao, Yan Li, Chuntao Ma

    Published 2025-05-01
    “…All participants will provide written informed consent, and the study will adhere to the principles of the Declaration of Helsinki. The findings will be published in a peer-reviewed journal. …”
    Get full text
    Article
  17. 157
  18. 158

    Guided self-determination intervention versus attention control for people with type 2 diabetes in outpatient clinics: a protocol for a randomised clinical trial by Christian Gluud, Jane Lindschou, Thordis Thomsen, Janus C Jakobsen, Vibeke Zoffmann, Anne Sophie Mathiesen, Tine Bruhn Skytte, Bodil Rasmussen, Emilie Marqvorsen, Mette Rothmann

    Published 2021-12-01
    “…We describe the protocol for a pragmatic randomised, dual-centre, parallel-group, superiority clinical trial testing a GSD intervention versus an attention control for people with type 2 diabetes in outpatient clinics. …”
    Get full text
    Article
  19. 159

    Effect of testosterone treatment during puberty in boys with Klinefelter syndrome (The TIPY Study): protocol for a nationwide randomised, double-blinded, placebo-controlled study by Gary Butler, Anders Juul, Judith L Ross, Jørgen Holm Petersen, Kurt Kristensen, Ann-Margrethe Rønholt Christensen, Ida Dyhr Caspersen, Andrés Felipe Østergaard Fritzbøger, Niels Birkebæk, Anders Jørgen Schou, Shanlee Davis, Sophie van Rijn, Lise Aksglaede

    Published 2025-03-01
    “…Neuropsychological assessment will be conducted at baseline and after 24 months of treatment.Ethics and dissemination The study will be conducted in accordance with the Helsinki Declaration. The study has been approved by the Danish National Medical Research Ethics Committee and the Danish Medicines Agency (Clinical trials information system number 2023-505854-16-00). …”
    Get full text
    Article
  20. 160

    Non-ischaemic preservation of the donor heart in heart transplantation: protocol design and rationale for a randomised, controlled, multicentre clinical trial across eight European... by Göran Dellgren, Filip Rega, Janne Brouckaert, Andreas Wallinder

    Published 2023-12-01
    “…This study will be conducted in accordance with current local regulations and international applicable regulatory requirements according to the principles of the Declaration of Helsinki and ISO14155:2020. Main primary and secondary outcomes will be published on modified intention-to-treat population and per-protocol population.Trial registration number NCT03991923.…”
    Get full text
    Article